Laurus Labs Ltd
NSE:LAURUSLABS

Watchlist Manager
Laurus Labs Ltd Logo
Laurus Labs Ltd
NSE:LAURUSLABS
Watchlist
Price: 566.1 INR 1.23% Market Closed
Market Cap: 305.2B INR
Have any thoughts about
Laurus Labs Ltd?
Write Note

Net Margin
Laurus Labs Ltd

2.6%
Current
11%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
2.6%
=
Net Income
1.3B
/
Revenue
50.5B

Net Margin Across Competitors

Country IN
Market Cap 305.1B INR
Net Margin
3%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 756.3B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 2.7T DKK
Net Margin
35%
Country US
Market Cap 349.7B USD
Net Margin
17%
Country US
Market Cap 251.6B USD
Net Margin
19%
Country CH
Market Cap 199.5B CHF
Net Margin
20%
Country UK
Market Cap 161.6B GBP
Net Margin
13%
Country CH
Market Cap 171.3B CHF
Net Margin
35%
Country US
Market Cap 151.4B USD
Net Margin
7%
No Stocks Found

Laurus Labs Ltd
Glance View

Market Cap
305.1B INR
Industry
Pharmaceuticals

Laurus Labs Ltd., an Indian pharmaceutical powerhouse, has etched its presence in the global pharma industry with a focus on delivering affordable and high-quality active pharmaceutical ingredients (APIs). Founded in 2005, the company's trajectory has been nothing short of remarkable, with an emphasis on research-driven production and sustainability. The Hyderabad-based conglomerate cultivates its core expertise within key therapeutic areas such as antiviral, cardiovascular, and oncology medications. By amalgamating scientific prowess with cutting-edge manufacturing facilities, Laurus Labs has positioned itself as a fundamental supplier in the fight against global ailments, providing APIs to some of the most critical generic pharmaceuticals worldwide. The company's commitment to health innovation is reflected in its robust portfolio of over 60 commercialized APIs, substantiating its pivotal role in the pharmaceutical supply chain. Adding another feather to its cap, Laurus Labs has ventured into the formulation business, manufacturing finished dosage forms that reach consumers directly. This vertical integration allows Laurus to capture a larger share of the pharmaceutical value chain, maximizing returns from its research and manufacturing capabilities. The company's foray into generic formulations has opened doors to new markets, particularly in challenging economies where cost-effective treatment is crucial. By leveraging its API expertise to produce effective, high-quality generic medications, Laurus Labs not only enhances its profitability but also adheres to its founding ethos of making healthcare accessible. With investments in research and development and a commitment to expanding its product line, Laurus Labs continues to strengthen its presence while nurturing partnerships globally, fueling its growth trajectory.

LAURUSLABS Intrinsic Value
393.12 INR
Overvaluation 31%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
2.6%
=
Net Income
1.3B
/
Revenue
50.5B
What is the Net Margin of Laurus Labs Ltd?

Based on Laurus Labs Ltd's most recent financial statements, the company has Net Margin of 2.6%.